此外,该研究还开发了人工智能卷积神经网络模型,根据数字化病理学区分这些亚型,以实现临床转化。 因此,该研究结果表明,激素受体阳性HER2阴性乳腺癌的复旦分子分型阐明了此类乳腺癌分子异质性机制,并且为激素受体阳性HER2阴性乳腺癌的精准治疗奠定了基础,故有必要进一步开展大规模临床研究进行验证。 激素受体阳性HER2阴性乳腺癌多组学分析 激素受体阳性HER2阴性乳腺癌多组学特征 四种亚型乳腺癌的临床特征和病理学特征 蛋白质组学分析揭示细胞周期信号传导通路为增殖型治疗靶点 激素受体阳性HER2阴性乳腺癌微环境特征 受体酪氨酸激酶驱动型癌症相关成纤维细胞可以促进肿瘤生长,并且容易受到索拉非尼的影响 Nat Genet. 2023 Sep 28. IF: 30.8 Molecular classification of hormone receptor-positive HER2-negative breast cancer. Xi Jin, Yi-Fan Zhou, Ding Ma, Shen Zhao, Cai-Jin Lin, Yi Xiao, Tong Fu, Cheng-Lin Liu, Yi-Yu Chen, Wen-Xuan Xiao, Ya-Qing Liu, Qing-Wang Chen, Ying Yu, Le-Ming Shi, Jin-Xiu Shi, Wei Huang, John F. R. Robertson, Yi-Zhou Jiang, Zhi-Ming Shao. Fudan University Shanghai Cancer Center, Shanghai, China; School of Life Sciences, Human Phenome Institute and Shanghai Cancer Center, Fudan University, Shanghai, China; International Human Phenome Institutes (Shanghai), Shanghai, China; Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai, China; University of Nottingham, Royal Derby Hospital, Derby, UK. Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding precision treatment. We established a large-scale multi-omics cohort of 579 patients with HR+/HER2- breast cancer and identified the following four molecular subtypes: canonical luminal, immunogenic, proliferative and receptor tyrosine kinase (RTK)-driven. Tumors of these four subtypes showed distinct biological and clinical features, suggesting subtype-specific therapeutic strategies. The RTK-driven subtype was characterized by the activation of the RTK pathways and associated with poor outcomes. The immunogenic subtype had enriched immune cells and could benefit from immune checkpoint therapy. In addition, we developed convolutional neural network models to discriminate these subtypes based on digital pathology for potential clinical translation. The molecular classification provides insights into molecular heterogeneity and highlights the potential for precision treatment of HR+/HER2- breast cancer. DOI: 10.1038/s41588-023-01507-7 全文共享 2021版CBCS指南与规范完整版 2021版CBCS指南与规范小程序